Archive · 21 Sep 2026
Government Launches Medicine-Safety Tools and Biovigilance Programme in India
The Indian government introduced new tools to help keep medicines and medical treatments safer.
These include a new edition of the National Formulary of India and a mobile app for reporting possible medicine side effects.
The government also approved a programme to watch for problems linked to transplant medicines and biological products.
Hospitals received guidance on reporting problems caused by medical devices.
The new formulary can be accessed online.
Officials said these systems will help collect and study safety information from across India.
They also said India now contributes more information to the World Health Organization’s patient-safety database.
The overall goal is to help patients receive safe, effective and appropriate medicines.
The Central government launched the 7th Edition of the National Formulary of India and the ADR-PvPI 2.0 iOS app.
A guidance document was released for hospitals reporting medical device-related adverse events.
The approved Biovigilance Programme of India will monitor adverse events linked to medicines and biological products used in transplantation.
The 7th National Formulary of India is available digitally through NFI Online.
Officials said pharmacovigilance, materiovigilance and biovigilance initiatives will strengthen safety monitoring across medicines, devices and transplant procedures.
- Who
- The Central government, Union Minister of State Anupriya Patel and the Indian Pharmacopoeia Commission launched the initiatives.
- What
- The government launched the 7th Edition of the National Formulary of India, the ADR-PvPI 2.0 iOS app and the Biovigilance Programme of India, and released medical-device safety guidance.
- When
- The launches took place on Monday during the 6th National Pharmacovigilance Week, observed from 17–23 September 2026.
- Where
- The programme was held in New Delhi.
- Why
- The initiatives aim to strengthen pharmacovigilance, patient safety, adverse-event reporting and the rational use of medicines.
- National formulary
- The 7th Edition of the National Formulary of India was launched and made available through NFI Online.
- Mobile app
- The ADR-PvPI 2.0 Mobile App was launched for iOS users.
- Biovigilance
- The Biovigilance Programme of India was approved to monitor adverse events involving transplant-related medicines and biological products.
- Medical devices
- Hospitals received guidance on monitoring and reporting medical device-related adverse events.
- Pharmacovigilance Week
- The 6th National Pharmacovigilance Week was observed from 17–23 September 2026.
- Global database contribution
- Anupriya Patel said India had moved from 123rd place during 2009–2014 to eighth globally in contributions to the WHO patient-safety database.
- Additional digital systems
- The government highlighted IP Online and the Adverse Drug Reaction Monitoring System alongside NFI Online and the ADR-PvPI app.